Ron Hause

Ron Hause is currently the Head of Computational Sciences at NewLimit, where they lead efforts in Computational Biology and Predictive Modeling to develop treatments aimed at restoring youthful function in aging human cells. Prior to this role, Ron contributed to the innovation of RNA therapeutics at ShapeTx and supported the development of cellular immunotherapies at Juno, Celgene, and Bristol Myers Squibb. They earned a PhD in Genetics from the University of Chicago and completed a Damon Runyon postdoctoral fellowship at the University of Washington, bringing over 15 years of experience in statistical genomics, machine learning, and therapeutic development. Throughout their career, Ron has emphasized collaboration across disciplines to enhance the efficacy of gene and cell therapies.